XOMA Royalty Corporation

XOMA Royalty Corporation is a biotech royalty aggregator operating in the United States, Switzerland, the Asia Pacific, and Australia. It holds economic rights to potential future milestone and royalty payments tied to commercial products and pre-commercial therapeutic candidates. The company also focuses on early- to mid-stage clinical assets, primarily Phase 1 and Phase 2 programs with commercial sales potential that are licensed to sponsors or developers, and acquires milestone and royalty revenue streams on late-stage clinical and commercial assets. Formerly known as XOMA Corporation, it changed its name to XOMA Royalty Corporation in July 2024. Incorporated in 1981, it is headquartered in Emeryville, California, and as of July 14, 2026, operates as a subsidiary of Ligand Pharmaceuticals Incorporated.